Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Subcutaneous Epratuzumab in Healthy Volunteers
NCT02306629Phase 1Completed
- Sponsor
- UCB
- Start
- Nov 2014
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of epratuzumab in systemic lupus erythematosus (SLE) (4 arms), sponsored by UCB. Primary endpoints: Area under the plasma concentration time curve from Baseline to time of last detectable concentration at Day 85, Area under the plasma concentration time curve from zero up to infinity at Day 85 and 2 more. Started Nov 2014; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02306629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306629.